ArticleResearch square2026
An Exploratory Study of Kinase Activation Profiles in Hypoxic Human Cardiomyocytes Treated with Protective Extracellular Vesicles.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Purpose: Myocardial infarction (MI) causes hypoxic cardiomyocyte death, and extracellular vesicles (EVs) offer therapeutic potential. This study aimed to compare kinase activation profiles induced by four human-derived EV types-serum-derived (S-EVs), platelet concentrate-derived (PC-EVs), cardiac stromal cell-derived (CSC-EVs), and bone marrow mesenchymal stromal cell-derived (MSC-EVs)- in hypoxic metabolically matured human iPSC-derived cardiomyocytes (iCMs). Methods: Metabolically matured human induced pluripotent stem cell-derived cardiomyocytes (iCMs) were exposed to 12-hour hypoxia ± standardized doses of EVs. Kinase activity was profiled using the PamStation platform, and bioinformatic tools (KRSA, UKA, PTM-SEA, KEA3) identified differentially activated kinases. AKT phosphorylation (Ser473) was measured by ELISA. Results: All EVs significantly reduced LDH release versus hypoxia alone (P ≤ 0.0001), with no inter-group differences. Hypoxia globally suppressed kinase activity, while each EV type induced distinct patterns: S-EVs and PC-EVs increased total phosphorylation, whereas CSC-EVs and MSC-EVs further decreased it. Bioinformatics implicated the AKT family in all treatments, but ELISA revealed no change in AKT1/2/3 phosphorylation at Ser473 versus hypoxia controls. Conclusion: Despite equivalent cardioprotection, each EV type elicited unique kinase activation profiles, suggesting distinct signaling mechanisms. Kinase activity was not a predictor of protection at the measured time point, highlighting the complexity of EV-mediated pathways.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.